STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early Alzheimer's disease with Leqembi (lecanemab), using a subcutaneous autoinjector (SC-AI),...
Hence then, the article about bla for subcutaneous formulation of leqembi designated for priority review in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China )
Also on site :